ObjectiveTo validate a modified HEART [History, Electrocardiograph （ECG）, Age, Risk factors and Troponin] risk score in chest pain patients with suspected non-ST-segment elevation acute coronary syndrome （NSTE-ACS...ObjectiveTo validate a modified HEART [History, Electrocardiograph （ECG）, Age, Risk factors and Troponin] risk score in chest pain patients with suspected non-ST-segment elevation acute coronary syndrome （NSTE-ACS） in the emergency department （ED）.Methods This retrospective cohort study used a prospectively acquired database and chest pain patients admitted to the emergency department with suspected NSTE-ACS were enrolled. Data recorded on arrival at the ED were used. The serum sample of high-sensitivity cardiac Troponin I other than conventional cardiac Troponin I used in the HEART risk score was tested. The modified HEART risk score was calculated. The end point was the occurrence of major adverse cardiac events （MACE） defined as a composite of acute myocardial infarction （AMI）, percu-taneous intervention （PCI）, coronary artery bypass graft （CABG）, or all-cause death, within three months after initial presentation.Results A total of 1,300 patients were enrolled. A total of 606 patients （46.6%） had a MACE within three months： 205 patients （15.8%） were diag-nosed with AMI, 465 patients （35.8%） underwent PCI, and 119 patients （9.2%） underwent CABG. There were 10 （0.8%） deaths. A progres-sive, significant pattern of increasing event rate was observed as the score increased （P ＆lt; 0.001 byχ2 for trend）. The area under the receiver operating characteristic curve was 0.84. All patients were classified into three groups： low risk （score 0-2）, intermediate risk （score 3-4）, and high risk （score 5-10）. Event rates were 1.1%, 18.5%, and 67.0%, respectively （P ＆lt; 0.001）.ConclusionsThe modified HEART risk score was validated in chest pain patients with suspected NSTE-ACS and may complement MACE risk assessment and patients triage in the ED. A prospective study of the score is warranted.展开更多
目的：评价和确定Braden-Q儿童压疮评估量表用于诊断住院患儿压疮高风险的最佳临界值。方法：对2014年1至6月在我院住院且Braden-Q量表≤24分的372例患者进行住院期间压疮发生情况追踪分析,采用灵敏度、特异度、阳性预测值、阴性预测值...目的：评价和确定Braden-Q儿童压疮评估量表用于诊断住院患儿压疮高风险的最佳临界值。方法：对2014年1至6月在我院住院且Braden-Q量表≤24分的372例患者进行住院期间压疮发生情况追踪分析,采用灵敏度、特异度、阳性预测值、阴性预测值、约登指数和受试者工作特征曲线（receiver operating characteristic,ROC）确定和评价Braden-Q量表诊断压疮高度危险的临界值。结果：372例研究对象中有37.73%的患者Braden-Q评分≤16分（最低11分）,72.27%的患者Braden-Q评分17～24分;共发生院内压疮21例,其分值主要集中在13～16分。当Braden-Q量表诊断压疮高危的临界值为16分时,其预测压疮危险的灵敏度为0.826,特异度为0.759,阳性预测值为0.185,阴性预测值为0.985,约登指数（0.585）较其他临界值更大,Braden-Q量表ROC曲线下面积（area under curve,AUC）为0.923。结论：Braden-Q量表16分是诊断儿童压疮高度危险的最佳临界值,能够很好地预测儿童发生压疮的风险,具有较高的诊断价值。展开更多
文摘ObjectiveTo validate a modified HEART [History, Electrocardiograph （ECG）, Age, Risk factors and Troponin] risk score in chest pain patients with suspected non-ST-segment elevation acute coronary syndrome （NSTE-ACS） in the emergency department （ED）.Methods This retrospective cohort study used a prospectively acquired database and chest pain patients admitted to the emergency department with suspected NSTE-ACS were enrolled. Data recorded on arrival at the ED were used. The serum sample of high-sensitivity cardiac Troponin I other than conventional cardiac Troponin I used in the HEART risk score was tested. The modified HEART risk score was calculated. The end point was the occurrence of major adverse cardiac events （MACE） defined as a composite of acute myocardial infarction （AMI）, percu-taneous intervention （PCI）, coronary artery bypass graft （CABG）, or all-cause death, within three months after initial presentation.Results A total of 1,300 patients were enrolled. A total of 606 patients （46.6%） had a MACE within three months： 205 patients （15.8%） were diag-nosed with AMI, 465 patients （35.8%） underwent PCI, and 119 patients （9.2%） underwent CABG. There were 10 （0.8%） deaths. A progres-sive, significant pattern of increasing event rate was observed as the score increased （P ＆lt; 0.001 byχ2 for trend）. The area under the receiver operating characteristic curve was 0.84. All patients were classified into three groups： low risk （score 0-2）, intermediate risk （score 3-4）, and high risk （score 5-10）. Event rates were 1.1%, 18.5%, and 67.0%, respectively （P ＆lt; 0.001）.ConclusionsThe modified HEART risk score was validated in chest pain patients with suspected NSTE-ACS and may complement MACE risk assessment and patients triage in the ED. A prospective study of the score is warranted.
文摘目的：评价和确定Braden-Q儿童压疮评估量表用于诊断住院患儿压疮高风险的最佳临界值。方法：对2014年1至6月在我院住院且Braden-Q量表≤24分的372例患者进行住院期间压疮发生情况追踪分析,采用灵敏度、特异度、阳性预测值、阴性预测值、约登指数和受试者工作特征曲线（receiver operating characteristic,ROC）确定和评价Braden-Q量表诊断压疮高度危险的临界值。结果：372例研究对象中有37.73%的患者Braden-Q评分≤16分（最低11分）,72.27%的患者Braden-Q评分17～24分;共发生院内压疮21例,其分值主要集中在13～16分。当Braden-Q量表诊断压疮高危的临界值为16分时,其预测压疮危险的灵敏度为0.826,特异度为0.759,阳性预测值为0.185,阴性预测值为0.985,约登指数（0.585）较其他临界值更大,Braden-Q量表ROC曲线下面积（area under curve,AUC）为0.923。结论：Braden-Q量表16分是诊断儿童压疮高度危险的最佳临界值,能够很好地预测儿童发生压疮的风险,具有较高的诊断价值。
